Medical Data Collector LinkDoc Could Face Cash Crunch After IPO Withdrawal

Oncology-focused information provider’s 12-month operating plan had included $200 million in IPO funds that it will no longer have Key points:  LinkDoc has indefinitely shelved its $211 million IPO, with no word on when or if it will eventually proceed Company had estimated IPO funds, combined with current cash and cash flow, would be enough to meet its needs for at least 12 months By Richard Barbarossa Chinese oncology-focused medical data firm LinkDoc Technology Ltd., which is backed by e-commerce giant Alibaba, was looking forward to marking a major milestone…

Read MORE »

Drug Maker I-Mab Wins Plaudits as Analysts Urge Caution on Soaring Stock

Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members Key points: I-Mab’s shares have nearly doubled over the past six months on major licensing deal, fundraising and pending drug approvals Appointment of two new well-connected board members could expedite first approvals of company’s drugs in China By Richard Barbarossa Cancer drug developer I-Mab (IMAB.US) has been on a roll this year. The company’s shares have nearly doubled in the past six months after it recorded its…

Read MORE »

Cosmetic Surgery Information Hub So-Young Dolls Up With Major Acquisition

Plan to buy 85% of Wuhan Miracle Laser System for $122 million would represent company’s biggest purchases since its 2019 IPO Key points: So-Young’s $122 million purchase of a laser medical equipment maker represents its biggest investment since its 2019 IPO Such investments could help to drive So-Young’s growth, though it needs to better articulate its acquisition strategy for investors By Doug Young Cosmetic surgery specialist So-Young International Inc. (SY.US) was probably hoping that news of the first major acquisition since its 2019 IPO would make it prettier to investors.…

Read MORE »

Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO

Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market Key points:  •      Hutchmed announces new approvals in China for two of its self-developed drugs in run-up to new $600 million listing in its home market •      All seven analysts polled by Bloomberg recommend ‘buy’ for the stock, as company tries to transforms from seller of third-party drugs to developer of its own products   By Alice Leung Hong Kong Billionaire Li Ka-shing usually gets what he wants…

Read MORE »

Pandemic Accelerates China’s Drive Into mRNA Treatments

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases Key points: High efficacy rates in preventing Covid-19 spark rush by Chinese companies into mRNA vaccines and treatments At least one Chinese-made mRNA Covid vaccine, backed by the military, is now in late-stage development  By Richard Barbarossa They may be late to the party, but that hasn’t stopped China’s drug makers from rushing into messenger RNA (mRNA) drug-making technology, which has won global fame for its use in creating highly effective…

Read MORE »

Drug Startups Eye Quicker Profits Under China’s New Fast-Track Approvals

Key changes designed to bring cutting-edge drugs more quickly to market have yet to ignite significant rally for money-losing startups Key takeaways: New fast-track approval system could bring cutting-edge drugs to market more quickly Changes could benefit startups with quicker approvals, and by letting them work with big foreign manufacturing partners By Richard Barbarossa A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutting-edge treatments more quickly…

Read MORE »

Investors Bet Big on Cancer Drug Infant Duality Biologics and Its Rockstar Founder

Company has raised $120 million in 18 months from A-list investors including Eli Lilly and domestic heavyweight WuXi Biologics Key takeaways Duality Biologics’ new $90 million funding just 18 months after its founding comes on the reputation of its founder and focus on a hot cancer treatment area Recent advances in antibody-drug conjugates (ADCs) have led to an uptick in drug approvals and tide of similar new fundraising By Richard Barbarossa If one person’s reputation can form the foundation for building a company, then Dr. John Zhu, whose young cancer…

Read MORE »

Pharmaron, I-Mab and Burning Rock Get Investor Validation From MSCI

Three up-and-coming Chinese pharma companies are among those included in latest adjustment for the index compiler’s China All Shares Index Key takeaways: MSCI’s addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential Inclusion typically represents validation for a company’s products and outlook By Richard Barbarossa Drug and healthcare R&D firms are well-represented in the latest round of additions to the MSCI China All Shares Index, highlighting the sector’s growth potential and strong fundamentals. Some new ascendants to the list are even…

Read MORE »

Undervalued Zai Lab on Licensing Binge to Boost Cancer Treatment Portfolio

With $860 million in new cash from a recent share sale, company seeks to accelerate approval and rollout of new cutting-edge treatments from abroad Key takeaways: Zai Lab’s revenue should continue to surge on new product approvals and inclusion of a core product on the National Reimbursement Drug List Company’s losses could continue to balloon as it pursues expensive new licensing deals at the cost of near-term profits By Richard Barbarossa Cancer and autoimmune drug specialist Zai Lab Ltd.(Nasdaq: ZLAB; 9688.HK) is poised to accelerate approval of new medicines and…

Read MORE »

Online Insurance Broker Waterdrop Makes Splash, Then Crash, in New York IPO

Company raises $360 million after pricing shares at the top of their range, only to see stock tank nearly 20% in trading debut Key points: Waterdrop’s position as a middleman insurance broker should help protect it from regulatory risk in China’s sensitive financial services sector The company’s strong IPO pricing, followed by a sharp selloff in its trading debut, reflect investor indecision about its growth prospects  By Doug Young Middlemen are creatures of little or no respect, often seen as parasites that profit from a gap between businesses and the…

Read MORE »